Sample size calculations for clinical trials

Wiley Interdisciplinary Reviews: Computational Statistics

Volumn 3, Issue 5, 2011, Pages 414-427

  Chow, Shein Chung ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL INVESTIGATION; CLINICAL RESEARCH; CLINICAL TRIAL; CLOSED FORM; DOSE RESPONSE; NON-INFERIORITY; PATIENT POPULATION; SAMPLE SIZES; SEQUENTIAL DESIGN; STATISTICAL INFERENCE; STUDY DESIGN; TREATMENT EFFECTS; TWO STAGE; TYPE I ERROR RATE;

DESIGN; MEDICAL APPLICATIONS; PATIENT TREATMENT; POPULATION STATISTICS;

EXPERIMENTS;

EID: 79961065910     PISSN: 19395108     EISSN: 19390068     Source Type: Journal    
DOI: 10.1002/wics.155     Document Type: Article

References (29)

1. Chow SC, Shao J, Wang H. Sample Size Calculation in Clinical Research. 2nd ed. New York: Chapman and Hall/CRC Press/Taylor & Francis; 2008.
2. Lachin JM, Foulkes MA. Evaluation of sample size and power for analysis of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986, 42:507-519.
3. Lakatos E. Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Control Clin Trials 1986, 7:189-199.
4. Wang H, Chow SC. A practical approach for parallel trials without equal variance assumptions. Stat Med 2002, 21:3137-3151.
5. Wang H, Chow SC, Li G. On sample size calculation for odds ratio in clinical trials. J Biopharm Stat 2002, 12:471-484.
6. Chow SC, Liu JP. Design and Analysis of Clinical Trials. 2nd ed. New York: John Wiley & Sons; 2003.
7. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987, 15:657-680.
8. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. 3rd ed. New York: Chapman and Hall/CRC Press/Taylor & Francis; 2008.
9. Chow SC, Shao J. A note on statistical methods for assessing therapeutic equivalence. Control Clin Trials 2002, 23:515-520.
10. Berger RL, Hsu JC. Bioequivalence trials, intersection-union tests and equivalence confidence sets (with discussion). Stat Sci 1996, 11:283-319.
11. Blair RC, Cole SR. Two-sided equivalence testing of the difference between two means. J Mod Appl Stat Methods 2002, 1:139-142.
12. Westlake WJ. Symmetric confidence intervals for bioequivalence trials. Biometrics 1976, 32:741-744.
13. Hsu JC. Constrained two-sided simultaneous confidence intervals for multiple comparisons with the best. Ann Stat 1984, 12:1136-1144.
14. Bofinger E. Expanded confidence intervals. Communications in Statistics-Theory and Methods 1985, 14:1849-1864.
15. Bofinger E. Expanded confidence intervals, one-sided tests and equivalence testing. J Biopharm Stat 1992, 2:181-188.
16. Brown LD, Hwang JTG, Munk A. An unbiased test for the bioequivalence problem. Ann Stat 1997, 25:2345-2367.
17. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analysis. Biometrics 1994, 50:1029-1041.
18. Chang M. Adaptive design method based on sum of p-values. Stat Med 2007, 26:2772-2784.
19. Jennison C, Turnbull BW. Group Sequential Tests with Applications to Clinical Trials. London/Boca Raton, FL: Chapman & Hall; 2000.
20. Chow SC, Chang M. Adaptive Design Methods in Clinical Trials. New York: Chapman and Hall/CRC Press/Taylor & Francis; 2006.
21. Chow SC, Shao J, Hu OYP. Assessing sensitivity and similarity in bridging studies. J Biopharm Stat 2002, 12:385-400.
22. Chow SC, Shao J. Inference for clinical trials with some protocol amendments. J Biopharm Stat 2005, 15:659-666.
23. Chow SC, Chang M, Pong A. Statistical consideration of adaptive methods in clinical development. J Biopharm Stat 2005, 15:575-591.
24. Chow SC. Controversial Issues in Clinical Trials. New York: Chapman and Hall/CRC Press/Taylor & Francis; 2011.
25. Uesaka H. Sample size allocation to regions in multiregional trial. J Biopharm Stat 2009, 19:580-594.
26. Quan H, Zhao PL, Zhang J, Roessner M, Aizawa K. Sample size considerations for Japanese patients based on MHLW guidance. Pharm Stat 2010, 9:100-112.
27. Kawai N, Stein C, Komiyama O, Li Y. An approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Inf J 2008, 42:139-147.
28. Ko FS, Tsou HH, Liu JP, Hsiao CF. Sample size determination for a specific region in a multi-regional trial. J Biopharm Stat 2010, 20:870-885.
29. Chow SC. Good statistics practice in drug development and regulatory approval process. Drug Inf J 1997, 31:1157-1166.